Study supports HPV (human papillomavirus) testing for equivocal cervical smears
This article was originally published in Clinica
A major US cervical cancer screening trial has produced strong evidence to show that testing for the human papillomavirus (HPV) in women with inconclusive cervical Pap smears is a viable means of identifying those who may be spared unnecessary colposcopy and follow-up.
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.